Use of the EMPOWER brochure to deprescribe sedative-hypnotic drugs in older adults with mild cognitive impairment
Open accessThe DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence-based mailed educational brochures about the harms of sedative-hypnotic use lead to discontinuation of chronic benzodiazepine use in older adults. It remains unknown whether patients with mild cognitive impairment (MCI) are able to understand the information in the EMPOWER brochures, and whether they achieve similar rates of benzodiazepine discontinuation. METHODS: Post-hoc analysis of the EMPOWER randomized, double-blind, wait-list controlled trial that assessed the effect of a direct-to-consumer educational intervention on benzodiazepine discontinuation. 303 community-dwelling chronic users of benzodiazepine medication aged 65-95 years were recruited from general community pharmacies in the original trial, 261 (86%) of which completed the trial extension phase. All participants of the control arm received the EMPOWER brochure during the trial extension. Normal cognition (n = 139) or MCI (n = 122) was determined during baseline cognitive testing using the Montreal Cognitive Assessment questionnaire. Changes in knowledge pre- and post-intervention were assessed with a knowledge questionnaire and changes in beliefs were calculated using the Beliefs about Medicines Questionnaire. Logistic regression was used to compare knowledge gained, change in beliefs and benzodiazepine cessation rates between participants with and without MCI. RESULTS: Complete discontinuation of benzodiazepines was achieved in 39 (32.0% [24.4,40.7]) participants with MCI and in 53 (38.1% [30.5,46.4]) with normal cognition (adjusted OR 0.79, 95% CI [0.45-1.38]). Compared to individuals with normal cognition, MCI had no effect on the acquisition of new knowledge, change in beliefs about benzodiazepines or elicitation of cognitive dissonance. CONCLUSIONS: The EMPOWER brochure is effective for reducing benzodiazepines in community-dwelling older adults with mild cognitive impairment. TRIAL REGISTRATION: 2010.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Direct educational interventions (e.g., brochures) can help engage older adults—including those with mild cognitive impairment—and their care partners in shared decision-making around BZD tapering and discontinuation.173”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [173]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553 · cited 3×
“The MoCA was chosen due to its high sensitivity and specificity for distinguishing normal individuals from those with MCI [11].”
BackgroundMethodInfluentialBy the American Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13702 · Cited by 2,609
The American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.03923.x · Cited by 2,578
Horne, R., Weinman, J., & Hankins, M. (1999) · Psychology & Health · doi:10.1080/08870449908407311 · Cited by 2,372 · cited 1×
“Beliefs about the necessity of taking benzodiazepines versus associated harms were measured by comparing the total scores on the specific section of the beliefs about medicines questionnaire [14].”
MethodTannenbaum, C., Martin, P., Tamblyn, R., Benedetti, A., & Ahmed, S. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.949 · Cited by 665 · cited 3×
“However, when provided with evidence-based information about harm in the form of a mailed educational brochure, 27% of chronic users discontinued benzodiazepines within 6 months in the EMPOWER trial [10].”
BackgroundMethodSelf-citationMild cognitive impairment: Disparity of incidence and prevalence estimates
Ward, A., Arrighi, H. M., Michels, S., & Cedarbaum, J. M. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.01.002 · Cited by 569 · cited 1×
“Over 1-in-5 community dwelling older adults have MCI at any given time, although the exact prevalence is difficult to estimate due to the variability in the criteria used, the source of subjects, the fluctuating nature of the condition and the reference standards [5, 6].”
BackgroundBenzodiazepine use and risk of Alzheimer's disease: case-control study
Billioti de Gage, S., Moride, Y., Ducruet, T., Kurth, T., Verdoux, H., Tournier, M., Pariente, A., & Begaud, B. (2014) · BMJ · doi:10.1136/bmj.g5205 · Cited by 558
Current Epidemiology of Mild Cognitive Impairment and Other Predementia Syndromes
Panza, F., D’Introno, A., Colacicco, A. M., Capurso, C. A., Parigi, A. D., Caselli, R. J., Pilotto, A., Argentieri, G., Scapicchio, P. L., Scafato, E., et al. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.8.633 · Cited by 310
Tannenbaum, C., Paquette, A., Hilmer, S., Holroyd-Leduc, J., & Carnahan, R. (2012) · Drugs & Aging · doi:10.1007/bf03262280 · Cited by 241
Self-citationBoyle, P. A., Yu, L., Wilson, R. S., Gamble, K., Buchman, A. S., & Bennett, D. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043647 · Cited by 214 · cited 1×
“Discussion Although previous research indicates that individuals with MCI perform significantly worse than controls in multiple aspects of medical decision-making [7, 8, 15], we did not detect any difference in response to the EMPOWER deprescribing brochure among older adults who met MOCA criteria for MCI.”
Method
Cited by
Ng, B. J., Le Couteur, D. G., & Hilmer, S. N. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0544-4 · Cited by 118
Scott, S., Twigg, M. J., Clark, A., Farrow, C., May, H. M., Patel, M., Taylor, J., Wright, D. J., & Bhattacharya, D. (2019) · Age and Ageing · doi:10.1093/ageing/afz133 · Cited by 86
“Patient focussed interventions such as the EMPOWER educational brochure may complement this approach through encouraging patient engagement in deprescribing [10].”
BackgroundQuek, H. W., Page, A. T., Lee, K., Lee, G. B., Hawthorne, D., Clifford, R. M., Potter, K., & Etherton‐Beer, C. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16200 · Cited by 85
Attitudinal predictors of older peoples’ and caregivers’ desire to deprescribe in hospital
Scott, S., Clark, A., Farrow, C., May, H. M., Patel, M., Twigg, M. J., Wright, D. J., & Bhattacharya, D. (2019) · BMC Geriatrics · doi:10.1186/s12877-019-1127-x · Cited by 63
“EMPOWER trial, which includes the behaviour change technique ‘information about health consequences’ [36].”
MethodIsenor, J. E., Bai, I., Cormier, R., Helwig, M., Reeve, E., Whelan, A. M., Burgess, S. V., Martin‐Misener, R., & Kennie‐Kaulbach, N. (2020) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2020.09.005 · Cited by 60
“…with complete discontinuation of benzodiazepine Assessment of whether cognitive status affected comprehension and success of Tannenbaum, 2014[17] Martin, 2017[70] Canada Clusterrandomized controlled trial Intervention: 92 NR NR Control: 85 NR NR Benzodiazepine discontinuation rates See…”
BackgroundInfluential
Metadata
- Authors
- Martin, P., & Tannenbaum, C.
- Affiliations
- Institut Universitaire de Gériatrie de Montréal (CA)
- Corresponding author
- Martin, Philippe
- Venue
- BMC Geriatrics
- Published
- 2017-01-31
- Volume
- 17
- Issue
- 1
- Pages
- 37-37
- ISSN
- 1471-2318 (ISSN-L)
- PMC
- PMC5282809
- OpenAlex
- W2580999687
- Cited by
- 41
- References
- 18
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 6 · 2023: 5 · 2022: 1 · 2021: 2 · 2020: 5 · 2019: 2 · 2018: 7
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- BMC Geriatrics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PolyU Institutional Research Archive (Hong Kong Polytechnic University) (submittedVersion, cc-by)
- Funders
- Canadian Institutes of Health Research (CIHR-2009MOP-201314-KTE)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- benzodiazepine discontinuation, sedative-hypnotic drugs, mild cognitive impairment, older adults, patient knowledge, medication beliefs, cognitive dissonance, community-dwelling older adults, drug-related harm
- MeSH terms
- Aged, Aged, 80 and over, Benzodiazepines, Double-Blind Method, Female, Humans, Hypnotics and Sedatives, Health Knowledge, Attitudes, Practice, Male, Pamphlets, Patient Education as Topic, Waiting Lists, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of the EMPOWER brochure to deprescribe sedative-hypnotic drugs in older adults with mild cognitive impairment. https://app.cochat.ai/papers/10.1186/s12877-017-0432-5
- The paper
- Martin, P., & Tannenbaum, C. (2017). Use of the EMPOWER brochure to deprescribe sedative-hypnotic drugs in older adults with mild cognitive impairment. BMC Geriatrics. https://doi.org/10.1186/s12877-017-0432-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.